摘要
背景:心脏再灌注损伤会造成毁灭性的后果。组蛋白脱乙酰基酶(HDAC)抑制剂是有效的细胞保护剂,但其在预防心脏损伤中的作用仍不明确。 目的:探讨HDAC抑制剂在体外心肌细胞缺氧-复氧(H/R)模型中的治疗潜力。 方法:对h9c2心肌细胞进行H/R处理,并用5μm等浓度的不同类别特异性和泛HDAC抑制剂进行治疗。用Western blot检测乙酰化组蛋白H3和α-微管蛋白的生物活性,作为浓度适宜性的指标。用甲基噻唑基四氮唑和乳酸脱氢酶分别测定细胞活力和细胞毒性。为了更好地确定最有效的药物tubastatin-a(tub-a)对雷帕霉素(mtor)途径效应器的磷酸肌醇3激酶(pi3k)/哺乳动物靶点和自噬程度的影响,进行了机械学研究。 结果:所有抑制剂均乙酰化了已知的靶蛋白(组蛋白H3和α-微管蛋白),提示浓度足以诱导生物学效应。在暴露于Tub-A的心肌细胞中发现细胞活力提高和细胞毒性降低,而其他HDAC抑制剂的细胞保护作用不一致。PI3K/mTOR通路中的促生存介质上调,经Tub-A处理的细胞自噬程度显著降低。 结论:hdac抑制剂可提高心肌细胞H/R模型的细胞存活率,其Ⅱb类抑制剂(tub-a)具有较好的细胞水平和药效。这种效应至少部分与促生存介质表达增加和自噬程度降低有关。
关键词: 组蛋白脱乙酰酶,组蛋白脱乙酰酶抑制剂,缺氧复氧,缺血再灌注损伤,心脏损伤。
Current Molecular Medicine
Title:Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury
Volume: 18 Issue: 10
关键词: 组蛋白脱乙酰酶,组蛋白脱乙酰酶抑制剂,缺氧复氧,缺血再灌注损伤,心脏损伤。
摘要: Background: Cardiac reperfusion injury can have devastating consequences. Histone deacetylase (HDAC) inhibitors are potent cytoprotective agents, but their role in the prevention of cardiac injury remains ill-defined.
Objective: We sought to determine the therapeutic potential of HDAC inhibitors in an in vitro model of cardiomyocyte hypoxia-reoxygenation (H/R).
Method: H9c2 cardiomyocytes were subjected to H/R and treated with various classspecific and pan-HDAC inhibitors in equal concentrations (5µM). Biological activity of inhibitors was determined, as a proxy for concentration adequacy, by Western blot for acetylated histone H3 and α-tubulin. Cell viability and cytotoxicity were measured by methyl thiazolyl tetrazolium and lactate dehydrogenase assays, respectively. Mechanistic studies were performed to better define the effects of the most effective agent, Tubastatin-A (Tub-A), on the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway effectors, and on the degree of autophagy.
Results: All inhibitors acetylated well-known target proteins (histone H3 and α-tubulin), suggesting that concentrations were adequate to induce a biological effect. Improved cell viability and decreased cell cytotoxicity were noted in cardiomyocytes exposed to Tub-A, whereas the cytoprotective effects of other HDAC inhibitors were inconsistent. Pro-survival mediators in the PI3K/mTOR pathway were up-regulated and the degree of autophagy was significantly attenuated in cells that were treated with Tub-A.
Conclusion: HDAC inhibitors improve cell viability in a model of cardiomyocyte H/R, with Class IIb inhibition (Tub-A) demonstrating superior cellular-level potency and effectiveness. This effect is, at least in part, related to an increased expression of prosurvival mediators and a decreased degree of autophagy.
Export Options
About this article
Cite this article as:
Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury, Current Molecular Medicine 2018; 18 (10) . https://dx.doi.org/10.2174/1566524019666190208102729
DOI https://dx.doi.org/10.2174/1566524019666190208102729 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry Pharmacological Adjuvant Therapies in Primary Coronary Interventions: Bivalirudin
Cardiovascular & Hematological Agents in Medicinal Chemistry Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Epigenomic Approach in Understanding Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Targeting Apoptotic Pathways in Myocardial Infarction: Attenuated by Phytochemicals
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design Simultaneous Determination of Six Components in Jingzhiguanxin Tablet by High-Performance Liquid Chromatography
Current Pharmaceutical Analysis Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Association between Apo B Levels in Mothers and in their Pre-school Age Offspring
Cardiovascular & Hematological Agents in Medicinal Chemistry